DIACOMIT CAPSULE

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

STIRIPENTOL

থেকে পাওয়া:

BIOCODEX SAS

এটিসি কোড:

N03AX17

INN (আন্তর্জাতিক নাম):

STIRIPENTOL

ডোজ:

250MG

ফার্মাসিউটিকাল ফর্ম:

CAPSULE

রচনা:

STIRIPENTOL 250MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

60

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

MISCELLANEOUS ANTICONVULSANTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0153530001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2012-12-21

পণ্য বৈশিষ্ট্য

_ _
_ _
_DIACOMIT stiripentol _
_Page 1 of 38 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DIACOMIT™*
stiripentol
Capsules, 250 mg and 500 mg, Oral
Powder for suspension, 250 mg and 500 mg, Oral
In-House Standard
Antiepileptic [N03AX17]
Biocodex SAS
7 Avenue Gallieni
94250 Gentilly
France
Imported/Distributed by:
Biocodex Canada Inc.
320 Harry Walker Parkway North, 14
Newmarket, ON, L3Y 7B4
Date of Initial Authorization:
December 19, 2012
Date of Revision:
July 14, 2021
Submission Control Number: 248895
*All trademark rights used under license
_ _
_ _
_ _
_DIACOMIT stiripentol _
_Page 2 of 38_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
07/2021
RECENT MAJOR LABEL
CHANGES............................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.3
Reconstitution
...................................................................................................
7
4.4
Administration......................................................................